Ohnoshi T, Ueoka H, Numata T, Kawahara S, Nishii K, Yonei T, Mima Y, Horiguchi T, Kiura K, Moritaka T
Department of Medicine, Okayama University Medical School, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Feb;28(2):190-6.
In order to assess the development of treatment of small cell lung cancer (SCLC), we analyzed a total of 183 patients who had been entered into our protocol studies since 1976. Between 1976 and 1981, 39 patients (20 LD and 19 ED) received COMP, a 4-drug combination of cyclophosphamide (CTX), vincristine (VCR), methotrexate and procarbazine. During the period, chest irradiation (RT) was optimal for those with LD. Between 1981 and 1986, 112 patients (56 each of LD and ED) were treated with a cyclic alternating chemotherapy (CT) of COMP and VAN, a 3-drug combination of etoposide (VP-16), adriamycin (ADM) and nimustine. In this study, we randomized patients with LD either to receive CT alone or CT plus RT of 40 Gy to assess the role of RT in the treatment of LD. Thereafter, a pilot study of CAV-PVP hybrid CT has been conducted in 32 patients (16 each of LD and ED), in which CTX, ADM and VCR were given on day 1 (CAV), and cisplatin on day 8 and VP-16 on days 8 and 9 (PVP). RT was administered mandatory to LD in this study.(ABSTRACT TRUNCATED AT 250 WORDS)
为了评估小细胞肺癌（SCLC）治疗方法的发展，我们分析了自1976年起纳入我们方案研究的总共183例患者。1976年至1981年期间，39例患者（20例局限期和19例广泛期）接受了COMP方案治疗，该方案是由环磷酰胺（CTX）、长春新碱（VCR）、甲氨蝶呤和丙卡巴肼组成的四联化疗方案。在此期间，胸部放疗（RT）对局限期患者是最佳选择。1981年至1986年期间，112例患者（局限期和广泛期各56例）接受了COMP方案和VAN方案的循环交替化疗（CT），VAN方案是由依托泊苷（VP-16）、阿霉素（ADM）和尼莫司汀组成的三联化疗方案。在本研究中，我们将局限期患者随机分为单纯接受化疗或接受40 Gy胸部放疗联合化疗两组，以评估放疗在局限期治疗中的作用。此后，对32例患者（局限期和广泛期各16例）进行了CAV-PVP混合化疗的初步研究，其中CTX、ADM和VCR在第1天给药（CAV），顺铂在第8天给药，VP-16在第8天和第9天给药（PVP）。在本研究中，局限期患者必须接受放疗。（摘要截选至250字）
